Orsiro – The First Hybrid Drug-eluting Stent, Opening Up a New Class of Drug-eluting Stents for Superior Patient Outcomes

Abstract

The Orsiro device is a hybrid drug-eluting stent that represents a new strategy in the treatment of coronary artery stenosis. Orsiro features a hybrid coating of passive and active components: the PROBIO passive coating seals the metal surface of the stent and prevents interaction with the surrounding blood and tissue, while the BIOlute active coating contains a highly biocompatible polymer that delivers a -limus drug over 12–14 weeks and degrades gently over one to two years, thereby avoiding increased inflammation. The stent backbone is the PRO-Kinetic Energy platform, which has a double-helix stent design and thin struts, bringing flexibility and ease of deliverability.